

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/773,332	02/09/2004	Gary T. Wang	09095.0009-01000	8910
22852	7590 02/01/2005		EXAMINER	
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER			HABTE, KAHSAY	
LLP 901 NEW Y	ORK AVENUE, NW		ART UNIT	PAPER NUMBER
WASHINGT	ΓON, DC 20001-4413		1624	
			DATE MAILED: 02/01/200	5

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
Office Action Summary		10/773,332	WANG ET AL.				
		Examiner	Art Unit				
		Kahsay Habte, Ph. D.	1624				
	communication app	ears on the cover sheet with the c	correspondence address				
Period for Reply	· 		(0) 50014				
after SIX (6) MONTHS from the mailing date If the period for reply specified above is less t If NO period for reply is specified above, the r Failure to reply within the set or extended per	DMMUNICATION. e provisions of 37 CFR 1.13 of this communication. han thirty (30) days, a reply maximum statutory period w iod for reply will, by statute, ee months after the mailing	6(a). In no event, however, may a reply be tinwithin the statutory minimum of thirty (30) day ill apply and will expire SIX (6) MONTHS from	res will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status							
1) Responsive to communicati	on(s) filed on						
2a) ☐ This action is FINAL .							
3) Since this application is in c							
closed in accordance with the	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4) Claim(s) 1-27 is/are pending	4) Claim(s) <u>1-27</u> is/are pending in the application.						
· · · · · · · · · · · · · · · · · · ·	4a) Of the above claim(s) is/are withdrawn from consideration.						
•	S) Claim(s) is/are allowed.						
6) Claim(s) is/are reject	Claim(s) is/are rejected.						
	Claim(s) is/are objected to.						
8) Claim(s) <u>1-27</u> are subject to	Claim(s) 1-27 are subject to restriction and/or election requirement.						
Application Papers			,				
9) The specification is objected	to by the Examiner	•.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11)☐ The oath or declaration is ob	jected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119			•				
	one of: priority documents priority documents		ion No				
<u> </u>	•	•	ed in this National Stage				
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
		·					
Attachmont/c\							
Attachment(s) 1) Notice of References Cited (PTO-892)		4) Interview Summary	(PTO-413)				
2) Notice of Praftsperson's Patent Drawing	Review (PTO-948)	Paper No(s)/Mail D	ate				
Information Disclosure Statement(s) (PT Paper No(s)/Mail Date	O-1449 or PTO/SB/08)	5) Notice of Informal F 6) Other:	Patent Application (PTO-152)				

Application/Control Number: 10/773,332 Page 2

Art Unit: 1624

DETAILED ACTION

1. Claims 1-27 are pending in this application. The preliminary amendment to the claims and the specification filed on 9/3/2004 is acknowledged.

Election/Restrictions

- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-25, drawn to formula I compounds, where R¹ or R³ in the chemical structure is pyridinyl, classified for example in class 546, subclass 258 and 268.1.
 - II. Claims 26-27, drawn to a method of ameliorating a pathology in a mammal selected from inflammatory diseases, an autoimmune disease, tumor metastasis, allograft rejection and reperfusion injury, classified in class 514, subclass various.

Inventions II and I are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the pyridyl compounds of Group I can be used for treating pain that is materially different process from the method recited in claims 26-27.

Art Unit: 1624

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Advisory Rejoinder

The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See

"Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

A telephone call was made to Ms. Maria Bautista on Jan. 12, 2005 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Conclusion

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kahsay Habte, Ph. D. whose telephone number is (571) 272-0667. The examiner can normally be reached on M-F (9.00AM- 5:30PM).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached on (571) 272-0674, if there is no reply within 24 hours, James Wilson (Acting SPE) can be reached at (571) 272-0661. The fax

Art Unit: 1624

phone number for the organization where this application or proceeding is assigned is (571)-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Kahsay Habte, Ph. D.

Examiner / Art Unit 1624

KH January 27, 2005